218 related articles for article (PubMed ID: 27866461)
1. Metabolism, excretion and pharmacokinetics of [
Lam JL; Vaz A; Hee B; Liang Y; Yang X; Shaik MN
Xenobiotica; 2017 Dec; 47(12):1064-1076. PubMed ID: 27866461
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
5. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
Shaik N; Hee B; Liang Y; LaBadie RR
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
[TBL] [Abstract][Full Text] [Related]
6. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Gerisch M; Hafner FT; Lang D; Radtke M; Diefenbach K; Cleton A; Lettieri J
Cancer Chemother Pharmacol; 2018 Jan; 81(1):195-206. PubMed ID: 29188322
[TBL] [Abstract][Full Text] [Related]
7. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
[TBL] [Abstract][Full Text] [Related]
9. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
[TBL] [Abstract][Full Text] [Related]
10. Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
Dymond AW; Howes C; Pattison C; So K; Mariani G; Savage M; Mair S; Ford G; Martin P
Clin Ther; 2016 Nov; 38(11):2447-2458. PubMed ID: 27751676
[TBL] [Abstract][Full Text] [Related]
11. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Disposition, and Biotransformation of [
Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R
Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and pharmacokinetics of indacaterol in humans.
Kagan M; Dain J; Peng L; Reynolds C
Drug Metab Dispos; 2012 Sep; 40(9):1712-22. PubMed ID: 22648561
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
Shaik N; LaBadie RR; Hee B; Chan G
Cancer Chemother Pharmacol; 2021 Feb; 87(2):241-250. PubMed ID: 33388951
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P
Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation Pathways and Metabolite Profiles of Oral [
Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
[TBL] [Abstract][Full Text] [Related]
18. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
20. Disposition and biotransformation of the antipsychotic agent olanzapine in humans.
Kassahun K; Mattiuz E; Nyhart E; Obermeyer B; Gillespie T; Murphy A; Goodwin RM; Tupper D; Callaghan JT; Lemberger L
Drug Metab Dispos; 1997 Jan; 25(1):81-93. PubMed ID: 9010634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
